RT Journal Article SR Electronic T1 Hydroxychloroquine use in the COVID-19 patient JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic DO 10.3949/ccjm.87a.ccc011 A1 Emily Littlejohn YR 2020 UL http://www.ccjm.org/content/early/2020/05/04/ccjm.87a.ccc011.abstract AB Hydroxychloroquine (HCQ) has multiple potential antiviral mechanisms of action that differ according to the pathogen studied (eg, Chikungunya, Dengue virus, human immunodeficiency virus, poliovirus, Zika virus). Data on HCQ for treatment of coronavirus disease 2019 (COVID-19) are rapidly evolving. To date there is no evidence from randomized controlled trials that any single therapy improves outcomes in patients infected with COVID-19. There are also no clinical trial data supporting prophylactic HCQ therapy in COVID-19. Hydroxychloroquine (HCQ) use in patients with COVID-19 is being investigated examining prophylaxis, postexposure prophylaxis, and treatment regimens.